LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Vinogradova, Yana; Coupland, Carol; Hippisley-Cox, Julia (2012)
Publisher: BMJ Publishing Group
Journal: BMJ Open
Languages: English
Types: Article
Subjects: 1723, Epidemiology, Protocol, 1692, 1717, 1506, 1724
Introduction: Bisphosphonates are becoming\ud a common treatment for osteoporosis particularly after\ud discovery of the association between hormone\ud replacement therapy and increased risk of breast\ud cancer. As osteoporosis develops with age, treatment\ud is a long-term intervention. Randomised control trials\ud typically have limited follow-up times, which restricts\ud investigation of the effects of the drugs on risk of\ud primary cancers. A few observational studies have\ud demonstrated a reduced risk of breast cancer and\ud possibly of endometrial cancer in bisphosphonate\ud users. Two epidemiological studies have studied the\ud effect of the drugs on oesophageal cancer but did not\ud reach any definite conclusions. So far, no effects on\ud colorectal and stomach cancer have been shown. This\ud study will investigate the association of\ud bisphosphonates with risks of the 10 most common\ud primary cancers.\ud Methods and analysis: A series of nested\ud caseecontrol studies will be based on the general\ud population using records from 660 UK general\ud practices within the QResearch Database. Cases will be\ud patients with primary cancers diagnosed between\ud 1996 and 2011. Each case will be matched by age, sex,\ud practice and calendar year to five controls, who are\ud alive and registered with the practice at the time of\ud diagnosis of the case. Exposure to bisphosphonates\ud will be defined as at least one prescription during the\ud study period. For the most common cancers with\ud substantial numbers of observations, the effect of the\ud duration of the treatment and different types of\ud bisphosphonates will be studied. Conditional logistic\ud regression will be applied to produce ORs adjusted for\ud smoking status, socioeconomic status, ethnicity,\ud cancer-specific co-morbidities and use of other\ud medications.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • http://bmjopen.bmj.com/content/suppl/2012/02/08/bmjopen-2011-000548.DC1.html This article cites 46 articles, 12 of which can be accessed free at: http://bmjopen.bmj.com/content/2/1/e000548.full.html#ref-list-1 Article cited in:
    • http://bmjopen.bmj.com/content/2/1/e000548.full.html#related-urls This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article